Biologics in Allergic/Immunologic Conditions, An Issue of Immunology and Allergy Clinics of North America
- 1st Edition, Volume 44-4 - October 14, 2024
- Imprint: Elsevier
- Editor: Flavia Hoyte
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 7 3 6 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 7 3 7 - 3
In this issue of Immunology and Allergy Clinics, guest editor Dr. Flavia Hoyte brings her considerable expertise to the topic of Biologics in Allergic/Immunologic Condition… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Immunology and Allergy Clinics, guest editor Dr. Flavia Hoyte brings her considerable expertise to the topic of Biologics in Allergic/Immunologic Conditions. Top experts provide an overview of the state of biologic treatments for autoimmune and allergic conditions including asthma, COPD, food allergies, atopic dermatitis; and more.
- Contains 13 relevant, practice-oriented topics including current and emerging biologics in CSU; biologics in AERD and ABPA; and multiple articles on biologics in asthma, including the role of biomarkers, the potential to achieve clinical remission, real-world studies, emerging biologics; and more.
- Provides in-depth clinical reviews on biologics in allergic/immunologic conditions, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Allergists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Foreword
- Preface
- Current and Emerging Biologics for Atopic Dermatitis
- Key points
- Introduction
- Overview of atopic dermatitis
- Pathophysiology of atopic dermatitis and implications for targeted therapy
- Currently approved biologics for moderate-to-severe atopic dermatitis
- Biologics in late stages of development
- Biologics targeting OX40/0X40 ligand
- Current guidelines
- Summary
- Clinics care points
- Chronic Spontaneous Urticaria: Current and Emerging Biologic Agents
- Key points
- Introduction
- Endotypes
- Therapies in management of chronic spontaneous urticaria targeting immunoglobulin E
- Therapies in management of chronic spontaneous urticaria targeting type 2 inflammation
- Summary
- Clinics care points
- Advancements in Biologic Therapies for Eosinophilic Gastrointestinal Diseases: A Comprehensive Review
- Key points
- Biologics in eosinophilic gastrointestinal diseases
- Summary
- Clinics care points
- Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis
- Key points
- Definitions
- Eosinophil-targeted biologics
- Biologics that indirectly impact eosinophils
- Approach to biologic therapy
- Clinics care points
- Biologics in Food Allergies: Emerging Therapies
- Key points
- Introduction
- Pathogenesis
- Discussion
- Summary
- Clinics care points
- Biologics in Chronic Rhinosinusitis: Current and Emerging
- Key points
- Introduction
- Endotyping in chronic rhinosinusitis
- Treatment strategy: role of medical and surgical management
- Approved biologic treatments for chronic rhinosinusitis
- Emerging therapies for type 2 and non-type 2 endotypes
- Summary
- Clinics care points/Pitfalls
- Biologics in Aspirin-Exacerbated Respiratory Disease and Allergic Bronchopulmonary Aspergillosis
- Key points
- Introduction
- Discussion
- Clinics care points
- Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations
- Key points
- Introduction
- Summary and future directions
- Clinics care points
- Biologics in Asthma: Role of Biomarkers
- Key points
- Introduction
- What are biomarkers?
- Historical background on the use of biomarkers in asthma
- Defining asthma endotypes
- Impact of biomarkers on asthma treatment
- Clinics care points
- Biologics in Asthma: Potential to Achieve Clinical Remission
- Key points
- Introduction
- What is remission?
- Definitions of clinical remission in asthma
- Studies looking at clinical remission of asthma with biologics
- The future of studying asthma
- Summary
- Clinics care points
- Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma
- Key points
- Introduction
- The importance of real-world studies in severe asthma
- Immunoglobulin E -targeted therapy
- Anti-interleukin 5/interleukin-5 receptor⍺ therapies
- Anti-interleukin 4/interleukin 13 pathway
- Anti-thymic stromal lymphopoietin
- Switching biologic therapies
- Dual biologic therapy
- Summary
- Clinics care points
- Biologics in Asthma: Emerging Biologics
- Key points
- Introduction
- Emerging therapies
- Challenges and barriers in drug delivery to the lungs
- Cold chain-related limitations of subcutaneous biologics
- Technological advances in biologic delivery
- Summary
- Clinics care points
- Edition: 1
- Volume: 44-4
- Published: October 14, 2024
- Imprint: Elsevier
- No. of pages: 240
- Language: English
- Hardback ISBN: 9780443297366
- eBook ISBN: 9780443297373
FH
Flavia Hoyte
Affiliations and expertise
Allergist and Immunologist, National Jewish Health, Division of Allergy and Clinical Immunology, Denver Colorado